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survival as well as acute and late toxicities were 
retrospectively analyzed. 
 
Results: Brachytherapy was performed as initially planned in 
all but one patient. 18 patients had a complete endoscopic 
response at the first follow-up examination. Loco-regional 
recurrence was observed in 24 patients after a median time 
of 3 months; 1- and 2-year recurrence-free survival rates 
were 51% and 51% for the patients treated for primary tumors 
and 11% and 6% for patients treated for tumor recurrence, 
respectively. Median overall survival was 18 months; 
estimated overall survival rates at 1, 2 and 3 years were 63%, 
50% and 30% after primary brachytherapy, and 60&, 25% and 
6% after treatment for recurrent cancers. Adenocarcinoma 
histology, non-complete remission after treatment and 
treatment for recurrent cancers were associated with 
significantly reduce prognosis. Mild to moderate dysphagia 
was the most common side effect in 17 patients; 8 patients 
suffered from loco-regional grade 3 toxicities, and no grade 4 
or 5 toxicities were observed. 
 
Conclusion: Endoluminal brachytherapy during the course of 
esophageal cancer treatment can be safely applied and 
results in good functional outcomes regarding dysphagia with 
moderate local toxicity and low side effects to the lung and 
heart. 
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Purpose or Objective: To describe the technique used in our 
department for treatment of cutaneous tumors with HDR 
plesiotherapy using custom moulds and to analyze long term 
results.  
 
Material and Methods: 
Custom made mould fabrication:  
We used this aplicator in irregular areas of skin.  
The treatment sequence is:  
- Creation of the mould with thermoplastic material with a 
thickness of 5 mm.  
- Parallel placement of transfer guide tubes with 1 cm of 
separation.  
- CT simulation and definition of the volume treat. The 
volume has to be delimited 5 mm in deep.  
- Dosimetry.  
- Treatment of the patient.  
We used 3 different schedules:  
- 54 Gy in 18 fractions  
- 66 Gy in 33 fractions  
- 40 Gy in 10 fractions 
 
Results: From September 2008 until September 2015 53 
patients had been treated with this technique.  
The average age was 77 years (63-91), the histology was 
squamous in 6 cases, basocellular in 46 cases, melanoma in 
situ in 1 case.  
The mean dose was 54.8 Gy (40-66). The treatment was 
adjuvant after surgery in 41,5% of the patients. 
After a mean time of follow up was 34,1 months there were 2 
local relapses (3.77%) in the treatment location. No deaths 
related to disease were observed. 
 
Conclusion: Treatment with HDR plesiotherapy using custom 
moulds is a technique used to treat small lesions and/or 
irregular surface locations. Planning with CT scan allows to 
know the dose in organs at risk using dose-volume histogram. 
This treatment offers a high local control of the disease and 
can be used alone or as adjuvant treatment after surgery in 
case of positive margins or presence of adverse factors. 
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Purpose or Objective: Previous literatures showed prior liver 
external beam radiotherapy (EBRT) may increase liver 
toxicity after yttrium-90 (90Y) selective internal radiation 
therapy (SIRT). In contrast, the safety of EBRT followed by 
SIRT is unclear. We investigated the safety and efficacy of 
EBRT followed by SIRT in hepatocellular carcinoma (HCC) 
patients. 
 
Material and Methods: Between October 2011 and May 2015, 
a total of 11 HCC patients who had treated with SIRT 
followed by liver salvage EBRT were enrolled. The SIRT 3-
dimensional absorbed dose distribution of each patient was 
retrospectively calculated on a voxel base, using post-
treatment bremsstrahlung SPECT/CT images. The physical 
dose and biological effective dose (BED) of SIRT and EBRT 
were generated and summed for evaluation. The dose-
volume histograms (DVHs) of the EBRT, SIRT, and combined 
therapy were analyzed. Liver-related toxicities were 
collected by chart-review and classified as Common 
Terminology Criteria for Adverse Events version 4. 
 
Results: The median time interval of SIRT and EBRT was 95 
days (IQR: 66.5-129.5 days). Eight patients (73%) had 
undergone EBRT for portal vein thrombosis (PVT) and 6 
patients (55%) for residual hepatic tumor. The mean SIRT, 
EBRT, and combined therapy normal liver BED were 
52.1±21.0 Gy, 17.9±6.1 Gy, and 69.5±15.0 Gy, respectively. 
The summed DVH of each patient is depicted in Figure 1. The 
image study three months post-irradiation showed primary 
disease PR in 4 patients (67 %) of patients and thrombosis 
improved in 6 patients (75%) after EBRT. Two patients had no 
evidence of disease after combined therapy. The median 
survival was 359.9 days. Total 3 patient (27 %) had developed 
≧grade 2 liver toxicities. Patient who experienced 
hepatotoxicity had higher summed BED (107.0±7.3 Gy vs 
58.9±13.5 Gy; P = 0.02). The univariate analysis of summed 
DVH showed that the fraction of normal liver exposed to 
more than 70 Gy (V70) was the strongest predictor of 
hepatotoxicity (9.4±7.2% vs 29.9±4.4%; P=0.007), as 
presented in Table 1.  
Figure 1: DVH of 11 patients 
 
 
 
Table 1. Dosimetric parameter univariate analysis 
